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1INTRODUCTION
A group of 14 patients suffering from nasopharyngeal carcinoma
(NPC) was first reported in 1901 (1) and the clinicopathological
features of 114 patients was published in 1941 (2). This malignan-
cy is a squamous cell carcinoma with varying degrees of differen-
tiation arising from the epithelial lining of the nasopharynx. It is
most frequently seen at the pharyngeal recess, the fossa of Rosen-
müller, situated medial to the medial crus of the Eustachian tube
opening in the nasopharynx (3, 4). 
NPC is common in southern China, especially the province of
Guangdong. The recent reported incidence of NPC among men
and women in Hong Kong (geographically adjacent to Guangdong
province) was 20 to 30 per 100,000 and 15 to 20 per 100,000
respectively (5). There is also increased incidence in northern
Africa and the Inuits of Alaska (6), but it is an uncommon dis-
ease in most countries, and its age-adjusted incidence for both
sexes is less than 1 per 100,000 (5). The incidence of NPC re-
mains high among Chinese who have immigrated to other parts
of Asia or North America, but is lower among Chinese born in
North America than in those born in southern China (7, 8). This
suggests that genetic, ethnic and environmental factors might
have a role in the etiology of this malignancy.  
SYMPTOMS AND SEROLOGICAL DIAGNOSIS
NPC patients frequently present with one or more of 4 groups
of symptoms, they are firstly nasal symptoms such as epistaxis,
nasal obstruction and discharge. This is related to the presence
of tumor mass in the nasopharynx; secondly, otologic symptoms
such as deafness and tinnitus related to the dysfunction of the
Eustachian tube caused by the latero-posterior extension of the
tumor to the paranasopharyngeal space. Thirdly, cranial nerve
palsies, commonly 5th and 6th cranial nerves, this is associated
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with the superior extension of the tumor leading to skull base
erosion; the patient might experience headache, diplopia, facial
pain and numbness. Fourthly, neck masses, they usually appear
in the upper neck. General symptoms of malignancy such as
anorexia and weight loss are uncommon in NPCs, and distant
spread should be suspected when these symptoms are present. 
A retrospective analysis of 4,768 patients identified the symp-
toms at presentation as neck mass (75.8%), nasal (73.4%), aural
(62.4%), headache (34.8%), diplopia (10.7%), facial numbness
(7.6%), weight loss (6.9%), and trismus (3.0%). The physical
signs present at diagnosis were enlarged neck node (74.5%), and
cranial nerve palsy (20.0%). The cranial nerves most common-
ly involved were the fifth, sixth, third and twelfth (9, 10). The
presenting symptoms in young patients were in general similar
to those in adults (11).
Unfortunately, as the nasal and aural symptoms are non-spe-
cific and also it is  a full clinical examination of the nasopharynx
is not easy, the majority of NPC patients are only diagnosed when
the tumor has reached an advanced stages. 
Where patients present with symptoms of NPC, they should
be clinically evaluated for physical signs of NPC. A positive Eps-
tein Barr virus (EBV) serology test will give further grounds for
suspicion and elevated copies of EBV DNA in the serum would
justify an endoscopic examination and a biopsy from the naso-
pharynx. 
A definitive diagnosis of NPC requires a positive biopsy taken
from the tumor in the nasopharynx, supported either by its visual-
ization in the nasopharynx.
PATHOLOGY
NPC in early years was called lymphoepithelioma, as the malig-
nant epithelial cells of the nasopharynx frequently intermingled
with lymphoid cells in the nasopharynx, giving rise to the term
lymphoepithelioma (12). Electron microscopy studies however
have determined that these tumor cells are of squamous origin
and the undifferentiated carcinoma is a form of squamous cell car-
cinoma with minimal differentiation (13, 14).
The histological classification of nasopharyngeal carcinoma pro-
posed by the World Health Organization (WHO) in 1978 cate-
gorized tumors into three types. Type I were the typical kera-
tinizing squamous cell carcinomas, similar to those found in the
rest of the upper aerodigestive tract. Type II included non-kera-
tinizing squamous carcinomas and type III were the undifferen-
tiated carcinomas (15). In recent years, an alternative classifica-
tion was proposed and this divided NPC into two histological ty-
pes, namely squamous cell carcinomas (SCCs) and undifferenti-
ated carcinomas of the nasopharyngeal type (UCNTs) (16). The
second classification is found to correlate with Epstein Barr virus
serology tests. Those patients with SCCs have a lower EBV titer,
while those with UCNTs have elevated titers. This classification
is more applicable for epidemiological research and has also been
shown to have a prognostic bearing. The undifferentiated carci-
nomas have a higher local tumor control rate with therapy, and
a higher incidence of distant metastasis (17, 18). In North Ameri-
ca, tumor histology in 25% of patients is Type I, 12% Type II,
and 63% Type III. The corresponding histological distribution in
southern Chinese patients is 2%, 3%, and 95% respectively (19). 
EBV is consistently detected in NPC patients from regions of
high and low incidence. Using EBV-encoded RNA (EBER) in situ
hybridization, EBER signal was present in virtually all tumor
cells. Premalignant lesions of the nasopharyngeal epithelium have
also been shown to harbor EBV, suggesting the EBV infection
occurs in the early phases of carcinogenesis (20). Specific EBV
latent genes are consistently expressed within the NPC tumors
and also in early, dysplastic lesions. 
Because of this association with EBV, EBV serology has been
used for population screening. In a study conducted in Wuzhou
(Guangxi province, China) in the early 1980s, 1,136 individuals
identified as IgA/VCA-positive received regular clinical exami-
nations of the nasopharynx and neck for a period of four years.
During this follow-up period 35 NPC cases were detected, most
of which (91.5%) were diagnosed early, at either stage I or stage
II. The annual detection rate of NPC for this group was 31.7 times
higher than for the population as a whole (21). The predictive
value of EBV serology for NPC was noted again recently. In
this study, the initial EBV serology of 9,699 study subjects was
cross-checked against the cancer registry and death registry
over a 15-yr period. It was found that the longer the duration
of follow-up, the greater the difference in the cumulative inci-
dence of nasopharyngeal carcinoma between seropositive and
seronegative subjects (22).
EPSTEIN BARR VIRUS DNA
Malignant cells have a high turnover rate and on cell lysis there
is an increased EBV DNA released into the blood. These circula-
ting free EBV DNA can now be detected by polymerase chain
reaction (PCR) in patients with NPC (23). The increased num-
ber of copies of EBV DNA found in the blood during the initial
phase of radiotherapy suggests that the viral DNA was released
into the circulation after cell death (24). The quantity of free
plasma EBV DNA as measured by real time quantitative PCR
has been shown to be related to the stage of the disease. The
detection of EBV DNA has been increasingly used for the diag-
nosis of NPC. For the detection of distant metastases, the use of
serum EBV DNA has been shown to be more sensitive and reli-
able than other options (25). The quantities of EBV DNA copies
before and after treatment are significantly related to the rates
of overall and disease-free survival (26, 27). There was a study
reporting that the levels of post-treatment EBV DNA when
compared with pretreatment EBV DNA had a better prediction
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for progression-free survival (28). When EBV DNA was empl-
oyed together with IgA against viral capsid antigen of Epstein
Barr virus increases the sensitivity of early diagnosis of naso-
pharyngeal carcinoma (29). Elevated levels of EBV DNA were
only detected in 67% of patients with locoregional recurrence
when the recurrence volume was small (30). 
IMAGING STUDIES
Clinical examination, including endoscopic examination of the na-
sopharynx can provide valuable information on mucosal involve-
ment and local tumor extension. It however cannot determine
deep extension of the tumor such as skull base erosion and intra-
cranial spread. 
Cross-sectional imaging has revolutionized the management of
NPCs. In terms of contribution to staging, CT can identified the
paranasopharyngeal extension as one of the most common mo-
des of extension of NPC (31), and perineural spread through the
foramen Ovale as an important route of intracranial extension.
Perineural spread through the foramen Ovale also accounts for
the CT evidence of cavernous sinus involvement without skull
base erosion (32).
Magnetic resonance (MR) is better than computed tomography
(CT) for displaying nasopharyngeal soft tissues and differentiat-
ing tumor from soft tissues, MR is also more sensitive at evalua-
ting retropharyngeal cervical nodal metastases (33) and also bone
marrow infiltration (34) MR, however, is of limited effectiveness
in evaluating bone details, and CT should be performed when the
status of the base of the skull needs evaluation (35). 
Imaging of distant metastases at diagnosis is less successful,
and a number of studies have concluded that bone scans (36),
liver scintigraphy (37), abdominal ultrasonography (38), and
marrow biopsy (39) are of little value in routine staging, The
role of positron emission tomography (PET) in the detection of
distant metastases in NPC and other malignancies has been es-
tablished (40). It has been reported that PET is more sensitive
than CT and MR at detecting residual and recurrent tumors in
the nasopharynx (41).
Cross-sectional imaging displays precisely the primary tumor
extent. This enables radiotherapy treatment to be administered
more accurately and effectively, and thus improved the outcome
(42). It has recently become possible to get even better results
with intensity modulated radiotherapy (IMRT), which makes use
of composite CT-MRI targets (43), and this enables radiotherapy
to be targeted even more accurately onto tumors and to spare
adjacent normal tissues.
STAGING
There were a few staging systems for NPC. The American Joint
Committee (AJC)/International Union Against Cancer (UICC)
system is preferred in Europe and America (44), while Ho’s sys-
tem is frequently used in Asia (45, 46). In the latter, its nodal clas-
sification has incorporated its prognostic significance, but its stra-
tification of the T stages into 5 sectors differs from other staging
systems. The development of a revised staging system in the past
decade was motivated by the desirability of incorporating exper-
iences gained from various centers around the world. It also take
into account a number of prognostic factors, such as skull base
erosion, involvement of cranial nerves (47), primary tumour ex-
tension to paranasopharyngeal space (48), and the level and size
of the cervical nodes (49). 
In 1997, a revised AJC/UICC staging system was published
(50). In this new staging system the T1 stage included tumors clas-
sified as both T1 and T2 under the old system. The new T2 stage
included tumors that had extended to the nasal fossa, oropharynx,
or paranasopharyngeal space. The new T3 stage covered tumors
that had extended to the skull base or other paranasal sinuses. The
new T4 stage covered tumors that had extended into the infra-
temporal fossa, orbit, hypopharynx, and cranium, or to the cranial
nerves. For cervical nodal staging, N1 under the new system re-
ferred to unilateral nodal involvement, N2 bilateral nodal disease
that had not reached N3 designation, irrespective of the size, num-
ber and anatomical location of the nodes. N3 referred to lymph
nodes larger than 6 cm (N3a), or nodes that had extended to the
supraclavicular fossa (N3b) (51). The new staging system has en-
abled patients to be staged more sensitively, and is a better pre-
dictor of survival (52, 53). 
PROGNOSTIC FACTORS
The tumor, nodes, and metastases (TNM) staging for NPCs is the
most important prognostic factor. Indeed, most other known pro-
gnostic factors are directly or indirectly related to the extent or
bulk of the tumor. 
A study reported in 1992 showed that the tumor’s histological
type and the radiotherapy dosage and coverage were also signi-
ficant independent prognostic factors (54). The histological type,
WHO Type I patients frequently seen among the Caucasian po-
pulation were found to be associated with adverse prognosis. 
Paranasopharyngeal extension was an independent prognostic
factor, correlated with adverse local tumor control and increased
distant spread (55) and this had been incorporated into the 1997
AJC/UICC stage system. 
A large variation of tumor volume is present in T stages and
primary tumor volume represents an independent prognostic fac-
tor of local control. It is more predictive with the AJC/UICC sta-
ging system than Ho’s T stage classification (56). Its validity has
been confirmed in patients with T3 and T4 tumors (57), and there
is an estimated 1% increase in risk of local failure for every 1 cm3
increase in primary tumor volume (58). Quantitative analysis of
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circulating EBV DNA in NPC has demonstrated a positive corre-
lation with disease stage and probably reflected the tumor load.
It has been shown to have prognostic importance (59).
Analyzing the different patterns of failure, different prognostic
categories can be defined across stages. T1-2N0-1 have relative-
ly good treatment outcome; T3-4N0-1 mostly local failure; T1-
2N2-3 mainly regional and distant failure and T3-4N2-3 have risk
of local, regional and distant failure (60).
TREATMENT
Radiotherapy
Unlike other head and neck cancers, radiotherapy instead of sur-
gery is the mainstay of treatment of NPC. NPC is highly radios-
ensitive and radiotherapy is the backbone of treatment for all sta-
ges of NPC without distant metastases. 
Conventional 2 dimensional (2D) radiotherapy for NPC de-
pends heavily on large lateral opposing fields. One of the most co-
mmon radiotherapy approaches for NPC is to start phase I treat-
ment with large lateral opposing facio-cervical fields that cover
the primary tumor and the upper neck lymphatics in one volume,
with matching lower anterior cervical field for lower neck lym-
phatics. The brainstem, spinal cord, eyes and oral cavity are pro-
tected by shieldings. When the spinal cord dose reaches 40-45
Gy, there are 2 options for phase II treatment. Treatment can ei-
ther be changed to lateral opposing facial fields with anterior fa-
cial field for the primary tumor, with matching anterior cervical
field for the neck lymphatics. Alternatively, treatment can be con-
tinued using the lateral opposing facio-cervical fields but with
shrinkage of fields to avoid the spinal cord, and by treating the
superior-posterior lymphatic with electron fields (61, 62). The
major objection to treating the primary tumor and the neck lym-
phatic in 2 separate volumes (both of these phase II treatment
techniques) is that there is a danger of underdosing the parana-
sopharyngeal extension of the tumor and the upper neck nodes
at the junction between the primary tumor and neck lymphatic
target volumes. Thus a paranasopharyngeal boost with a poste-
rior oblique field is often employed. Radical dose of 65-75 Gy is
normally given to the primary tumor and 65-70 Gy to the involv-
ed neck nodes, while the dose for prophylactic treatment for a
node-negative neck is 50-60 Gy. 
Conventional 2D radiotherapy successfully controlled T1 and
T2 tumors in between 75% to 90% of cases, and T3 and T4 tu-
mors in 50% to 75% of cases (63, 64). Nodal control is achiev-
ed in 90% for N0 and N1 cases, but the control rate drops to 70%
for N2 and N3 cases (63). As interrupted or prolonged treatment
reduces the benefits of radiotherapy, every effort should be made
to maintain the treatment schedule (65).
Because of the high incidence of occult neck node involvement,
prophylactic neck radiation is usually recommended (66). Good
loco-regional control should be the prime objective of treatment,
as loco-regional relapses represent a significant risk factor for the
development of distant metastases (67).
For T1 and T2 tumors, a booster dose using intracavitary bra-
chytherapy improved tumor control by 16% (64). Although ster-
eotactic radiosurgery has also been used for the booster dose (68,
69), it is probably better reserved for the treatment of persistent
and recurrent NPCs, because of the undesirable side effects asso-
ciated with hypofractionated treatment (70). 
Radiotherapy for NPC is challenging because the NP is anato-
mically surrounded by an array of radiosensitive structures like
the brain stem, spinal cord, pituitary-hypothalamic axis, tempo-
ral lobes, eyes, middle and inner ears, and parotid glands. As NPCs
tend to infiltrate and spread towards these normal organs, the ir-
radiation target volumes in NPC are very irregular. With conven-
tional lateral opposing fields, protection of adjacent radiosensitive
organs while giving high dose to targets is difficult. Often only the
critical organs like brainstem, optic pathway and spinal cord are
safeguarded with adequate shieldings to avoid unacceptable ra-
diation toxicities while non-critical organs like the parotids and
auditory pathway are sacrificed during radiotherapy. For patients
with early disease, since they have a good chance of survival, ra-
diation toxicities in these even non-critical structures would affect
the quality of life of survivors. However, for patients with local-
ly advanced disease like those with skull base infiltration or intra-
cranial extension, the challenge lies in achieving adequate tumo-
ricidal dose to the primary without overdosing the critical organs.
The major limitations of conventional 2D radiotherapy for NPC
can now be overcome with 3 dimensional (3D) conformal radio-
therapy and IMRT (71, 72). IMRT is an advanced form of 3D con-
formal radiotherapy, conforming high dose to tumor while con-
forming low dose to normal tissues. 3D conformal radiotherapy
employs multiple beams conforming to the shape of the target.
In additional of using multiple shaped conformal beams, IMRT
also allows for fine modulation of radiation intensity within each
radiation beam. Thus, in effect, there are thousands of beamlets,
each with calculated intensity to deposit a defined dose at each
specific point. A good therapeutic ratio can be achieved by giv-
ing a high dose to the tumor to achieve high local control prob-
ability while keeping down normal tissue complications by lim-
iting radiation dose to normal tissues. Also, IMRT planning and
dose optimization is fully computerized, a process known as in-
verse planning, thus it is much preferred over the more exper-
tise dependent forward planning in 3D conformal radiotherapy. 
The use of IMRT in treatment of NPC have multiple advan-
tages. Firstly, IMRT can be used for organ preservation, e. g. spar-
ing the parotids of high dose radiation will preserve salivary fun-
ction after radiotherapy; Secondly, in the case of extensive tu-
mors, and when the tumor extension was close to the dose-lim-
iting organs, IMRT can achieve good dose differential between
the tumor and the dose-limiting organs (73, 74), and thus can ach-
ieve high dose in tumor without overdosing the normal organs.
This also opens up a therapeutic window for dose escalation in
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the tumor to improve local control. Thirdly, IMRT allows differ-
ential doses to be given to different targets/organs simultaneous-
ly, thus different targets/organs can receive different fractional
dose at the same fraction of treatment. As the fractional dose will
affect the biological effectiveness of radiation (75), there is a com-
ponent of biological modulation of radiation besides just modu-
lating the physical radiation dose in IMRT. Simultaneous modu-
lated accelerated radiotherapy (SMART) employs this principle
for accelerated radiotherapy with IMRT (76). Fourthly, IMRT re-
solves the problem of dose uncertainty at the junction between
the primary tumor and neck lymphatic target volumes in conven-
tional radiotherapy. It enables the primary tumor and the upper
neck nodes to be treated in one volume throughout. For the above
reasons, IMRT also eliminates the need of boost and hyperfrac-
tionation. Radiotherapy course can be shortened and is more effi-
cient.
Different series reported excellent local control of more than
90% in NPC achieved with IMRT (77-81), even among patients
with advanced T3-4 diseases (82). Reports also shown preserva-
tion of salivary function and improve quality of life of survivors
after IMRT (83-85). A recent multicentre study also showed that
the excellent 90% local control rate with IMRT as reported from
single institutions are reproducible in multi-institutional setting
(86). Thus, IMRT has gradually evolved as the new standard of
care for NPC.
Chemotherapy
While modern radiotherapy like IMRT achieves good local con-
trol, distant metastases become the predominant pattern of fail-
ure, especially among those with loco-regionally advanced dis-
ease. NPC is also chemosensitive. There is a long history of clini-
cal studies investigating combined radiotherapy (RT) and chemo-
therapy for NPC. Most of the early studies were non-randomized
and the results are conflicting or inconclusive (87-96). Up to the
year 1998, there were only 5 reported randomized trials on com-
bined chemotherapy and RT for NPC (87, 90, 92, 95, 96). Each
trial used a different approach with respect to drug combination,
time sequence of chemotherapy and RT, and RT technique and
dose. In the early randomized trials, induction chemotherapy is
the most often studied combination (90, 92, 96). The rationale for
induction chemotherapy is to reduce tumor load of loco-regional
disease before start of RT and also early use of systemic treatment
for eradication of micro-metastases. The only induction trial that
showed a significant improvement of disease-free survival was
the International Nasopharyngeal Carcinoma Study Group (92),
using combination of bleomycin, epirubicin and cisplatin. How-
ever, there was no improvement in overall survival. This discrep-
ancy in findings for disease-free and overall survival may be due
to the increased treatment-related death among patients on induc-
tion chemotherapy which would offset the benefit of chemothe-
rapy in reducing disease-related death. 
A pivotal study was reported by the Head and Neck Inter-
group in 1998, using concurrent RT with cisplatin (100 mg/sqm
D1, 22, 43) followed by adjuvant cisplatin and 5-fluouracil (5-
FU) (cisplatin 80 mg/sqm D1 and 5-FU 1,000 mg/sqm /D, D1-
4, Q4 weeks cycles for 3 cycles) (95). Compared with RT alone,
chemoradiation significantly improved progression free survival
and overall survival. The pattern of disease failure showed re-
duction of both loco-regional and distant failure with chemora-
diation. 
There was initial skepticism of the Intergroup results and dou-
bts if the results were applicable to NPC in the endemic areas.
After report of the Intergroup 0099 Study, randomized trials
using similar design were performed in endemic regions in Asia,
to validate the Intergroup results. Three randomized trials were
subsequently reported from Hong Kong (97), Singapore (98),
and China (99) respectively. The study from HK used the same
chemotherapy regime as the Intergroup study and showed im-
proved failure-free survival mainly due to improved local con-
trol with chemoradiation. However, distant control and overall
survival showed no significant difference (97). On the other hand,
the Singapore and China studies both used a variation of dosing
of cisplatin from the Intergroup regime, employing lower dose
of cisplatin but given more frequently. The Singapore and Guang-
zhou trials both showed significant reduction of distant metas-
tases and improvement of both disease-free and overall survival
with chemoradiation (98, 99). 
The meta-analysis of chemotherapy in nasopharyngeal carci-
noma (MAC-NPC) study of the MAC-NPC Collaborative Group
is the only meta-analysis that used an individual patient data de-
sign (100). As reported in 2006, the MAC-NPC study included
8 randomized trials which had completed accrual before end of
2001 and thus excluded the more recent trials from Asia. In the
meta-analysis, there were 4 trials that investigate induction che-
motherapy (+ adjuvant chemotherapy in 1 trial), 3 trials that in-
vestigate concurrent chemoradiotherapy (+ adjuvant chemothe-
rapy in 2 trials) and 1 trial that investigate adjuvant chemother-
apy alone. Overall, an absolute survival benefit of 6% at 5 yr
from addition of chemotherapy was observed (from 56% to 62%).
A significant interaction was observed between the timing of che-
motherapy and overall survival, with the highest benefit result-
ing from concurrent chemoradiation. The results concur with fin-
dings from meta-analysis on other head and neck cancers also. 
There is now general agreement that the positive results repor-
ted in the Intergroup 0099 study are applicable to the NPC in the
endemic areas, but the conflicting evidence of chemotherapy on
local control and distant metastases have generated discussion.
The conclusion seems to be that, of the three basic approaches
tested in these studies (induction, concurrent, and adjuvant che-
motherapy), concurrent chemoradiotherapy is the most effica-
cious. There were 3 randomized trials that evaluated adjuvant
chemotherapy and all were negative (87, 101, 102). Thus, there
is still debate on whether the adjuvant chemotherapy in the Inter-
group regime can be omitted. 
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SEQUELAE OF THERAPY
Survivors of NPC following radiotherapy or chemoradiation have
impaired health-related quality of life (103, 104). Patients may
suffer from a variety of late complications, many of which result
from the effects of radiation on the dose-limiting organs situat-
ed adjacent to the nasopharynx and cervical lymph node. The use
of chemotherapy in more advanced cases adds to the side effects,
which include ototoxicity associated with cisplatin. A small pro-
portion of the long-term sequelae represent the effects of unheal-
ed residual damage by the tumor, such as residual cranial nerve
palsies, and serous otitis media resulting from persistent distur-
bance of the Eustachian tube function. 
These sequelae include auditory (105) problems, neuro-endo-
crine (106) disturbances and oral complications such as, dry mou-
th, poor oral and dental hygiene (107, 108). Radiation-induced
soft tissue fibrosis (109), and even carotid artery stenosis might
develop in the long term (110). The most debilitating sequelae are
neurological complications and may include temporal lobe necro-
sis (111), and cranial nerve palsies (112) These lead to symptoms
of dysphagia (113), and memory (114), cognitive (115), and neu-
ropsychological dysfunctions (116). 
A series of cases in which hypofractionated radiotherapy was
used in combination with conventional 2D radiotherapy produ-
ced a 60% actuarial risk of complication and a 28% risk of neu-
rological complications (117). Cutting down late complications
of treatment should be one of the main objectives of future clini-
cal trials. It has been demonstrated that shielding of the pituitary
-hypothalamic axis in 2D planning and treatment can significan-
tly reduce neuro-endocrine complications (118). Use of IMRT has
been shown to improve salivary function (80, 84), but other bene-
fits may require a longer follow-up period to confirm. 
MANAGEMENT OF RESIDUAL OR 
RECURRENT DISEASE
Despite the improved results of concomitant chemoradiation in
the management of nasopharyngeal carcinoma, there are still
some patients who developed local or regional failure presenting
as persistent or recurrent tumor. Early detection is essential for
any form of salvage therapy to be successful. FDG-PET is supe-
rior to other imaging studies such as computed tomography or
MRI in detecting residual or recurrent disease in the nasopharynx
(119) and this can usually be confirmed with biopsy through en-
doscopic examination. Residual or recurrent tumor in the cervi-
cal lymph nodes after radiotherapy is however notoriously dif-
ficult to confirm, as in some lymph nodes only clusters of tumor
cells are present (120). Sometimes the diagnosis was only con-
firmed after salvage surgery.
Aggressive salvage treatment for locally recurrent NPC is war-
ranted, especially when the disease is confined to the nasophar-
ynx. Survival after retreatment for more extensive disease re-
mains poor, but is still higher than in patients receiving support-
ive treatment only (113). Even for patients with synchronous
loco-regional failures, aggressive treatment should be consid-
ered for selected patients (121). 
Disease in the neck 
Following concomitant chemoradiation for nasopharyngeal car-
cinoma, isolated failure in the neck was much reduced and it was
less than 5% (122). If cancer persists or recurs in the cervical lym-
ph nodes as evidenced by imaging studies or clinical progression
of the lymph nodes, salvage therapy is indicated. When external
radiotherapy was employed as the salvage option, the overall 5-
yr survival rate was 19.7% (123). Surgical salvage in the form
of radical neck dissection could achieved a 5-yr tumor control
rate of 66% in the neck and a 5-yr actuarial survival of 38%
(124). When tumor in the neck lymph node exhibits extracapsu-
lar spread, brachytherapy should be applied to the tumor bed fol-
lowing radical neck dissection. With this adjuvant therapy, a simi-
lar tumor control rate has been achieved as when radical neck
dissection was carried out for less extensive neck disease (125).
Disease in the nasopharynx
When the patient was detected to have residual or recurrent tu-
mor in the nasopharynx after radiation or chemoradiation, this
can be managed with a second course of external radiotherapy.
This radiation dosage should be greater than the initial one and
although a salvage rate of 32% has been achieved, the cumula-
tive incidence of late post-reirradiation sequela was 24%, with
treatment mortality of 1.8% (126). In view of the high incidence
of complications resulting from the second course of radiation,
stereotactic radiotherapy, brachytherapy and surgical resection
have been employed for the salvage of small localized tumors in
the nasopharynx. Stereotactic radiotherapy under these circum-
stances have a 72% 2-yr local tumor control rate (77). The number
of patients treated with this method was small and long-term fol-
low-up information is not available (127).
Brachytherapy
With the application of brachytherapy, the radiation dose decr-
eases rapidly from the radiation source, enabling a high dose of
irradiation to be delivered to the residual or recurrent tumor
but a much smaller dose to surrounding tissue. Brachytherapy
also delivers radiation at a continuous low dose rate, which gives
it a further radiobiological advantage over fractionated external
radiation. Intracavitary brachytherapy has been used for naso-
pharyngeal carcinomas (128). The radiation source was placed
either in a tube or a mould before insertion into the nasophar-
ynx. In view of the irregular contour of the nasopharynx and
the uneven surface of the recurrent or residual tumor, it is diffi-
cult to apply the radiation source accurately to provide a tumo-
ricidal dose. To circumvent this problem, interstitial radioactive
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implants have been used to treat those small localized residual
or recurrent tumor in the nasopharynx (129). 
The most frequently employed radiation source for this purpo-
se is the radioactive gold grains (198Au). These gold grains can
be implanted into the tumor in the nasopharynx either transnasal-
ly or using the split-palate approach (130). The latter approach
gives the surgeon a direct view of the tumor and enables the
implantation of the radioactive gold grains into the tumor pre-
cisely to give a better dosimetry of radiation. For those small
tumors localized in the nasopharynx, without bone invasion,
this method has provided effective salvage with minimal mor-
bidity (131). The efficacy of the gold grain implants to treat per-
sistent and recurrent tumors after radiotherapy was reported to
give a 5-yr local tumor control rates of 87% and 63% respec-
tively. The corresponding 5-yr disease-free survival rates were
68% and 60% respectively (132). Other treatments for man-
agement of localized disease with intracavitary brachytherapy
have also been reported with success (133, 134). 
Nasopharyngectomy
Surgical resection of the residual or recurrent tumor in the naso-
pharynx is another salvage option. It is indicated when the locali-
zed disease cannot be managed by brachytherapy either it is too
extensive or it is located at a position, such as the cartilage of the
Eustachian tube crus where gold grains cannot be implanted.
When the tumor has extended to the paranasopharyngeal space,
then surgical resection is indicated. Nasopharyngectomy in select-
ed patients with localized disease is a good option of salvage. The
nasopharynx, is located in the middle of the head and because of
its awkward position, the exposure of the tumor in the nasophar-
ynx for oncologic extirpation has been a difficult technical chal-
lenge. A number of approaches have been reported, including
the anterior approach via the Le Forte I or the midfacial deglove
route, an infratemporal approach from the lateral aspect (135),
transpalatal, transmaxillary and transcervical approaches from
the inferior aspect (136, 137), and an anterolateral approach (138).
The mortalities associated with these salvage surgical procedures
have been low, and as all the patients concerned had previously
undergone radical radiotherapy, some patients develops trismus
and palatal fistula. These morbidities lead to some degree of in-
convenience but were still acceptable (139). With modification of
surgical techniques, the palatal fistula rate associated with the ma-
xillary swing approach has been marked reduced (140). As long as
the residual or recurrent tumor can be removed adequately, the
long-term results have been satisfactory. The 5-yr actuarial con-
trol of tumors in the nasopharynx has been reported to be around
65% and the 5-yr disease-free survival rate is around 54% (141,
142). In recent years, there were reports of removal of small re-
current tumor with the help of the endoscope (143, 144). The
tumor has to be located at appropriate site in the nasopharynx
before an oncologic resection can be performed for these patients
and so far the number reported were small (145). 
External radiotherapy
For more advanced or infiltrative tumors, a second course of
external radiotherapy is required (146). A second course of exter-
nal radiotherapy administered concurrently with chemotherapy
has been tried; this was built on the experience gained from the
use of concurrent chemoradiotherapy in primary treatment. This
treatment has been reported to give a 5-yr actuarial overall sur-
vival rate of 26%, though the risk of major late toxicities was
significant (147). The use of precision radiotherapy such as IMRT
may improve the therapeutic ratio for local control, promising
initial results have been reported (148), but distant metastases
will remain a major issue for patients suffering from local relapse.
DISTANT METASTASIS
Despite the use of concurrent chemoradiotherapy, distant metas-
tases remain the major cause of failure, and the prognosis for stage
IV patients remains grim (149). The meta-analysis on head and
neck cancer also showed that concurrent chemoradiation is the
most effective sequence in combining chemotherapy and radio-
therapy (150). However, induction chemotherapy showed signif-
icant reduction of distant failures (150). Thus, there is now revi-
val of interest in using induction and concurrent chemotherapy in
treatment of NPC. The Hong Kong NPC Study Group is curren-
tly still recruiting patients in a randomized trial NPC 0501 com-
paring induction and concurrent chemotherapy vs. concurrent
and adjuvant chemotherapy (151). The results of this trial will
shed more light on the optimal sequence of combining radiother-
apy with chemotherapy.
Another approach to reduce distant failure is by adding target-
ed therapy to chemotherapy. In a recently closed, phase II trial
(RTOG 0615) (152), bevacizumab (a monoclonal antibody direct-
ed against vascular endothelial growth factor) was added to the
concurrent and adjuvant phases of therapy. It was hoped that ad-
ding on anti-angiogenic agents to the primary treatment can ster-
ilize distant micrometastases in primary treatment.
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